関連する実験動画

Updated: Feb 20, 2026

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.4K

網膜疾患に対するバイオシミラー抗血管内皮成長因子の有効性と安全性:体系的なレビューとメタ解析

Bhadra U Pandya1, Andrew Mihalache1, Ryan S Huang1

  • 1Temerty Faculty of Medicine, University of Toronto, Ontario, Canada.

Retina (Philadelphia, Pa.)
|February 18, 2026
PubMed
まとめ

バイオシミラー抗血管内皮成長因子 (VEGF) 注射は,網膜疾患に対する参照の抗VEGF治療と比べて,安全性と視覚的な成果を提示しています. 多様な集団における長期的な評価については,さらなる研究が必要である.

キーワード:
アフリバーセプトとはAnti-VEGFFは,動物性であるため,動物性である.バイオシミラー バイオシミラー糖尿病性マキュラ腫 (糖尿病性マキュラ腫) とは神経血管性年齢関連のマキュラ変性ラニビズマブ (ラニビズマブ) とは網膜静脈閉塞による網膜静脈閉塞

さらに関連する動画

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.6K

関連する概念動画

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
292
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288